12 completed, 5 recruiting, 3 active not recruiting, 1 not yet recruiting. 23 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 23 | Completed 12, Recruiting 5, Active not recruiting 3, Not yet recruiting 1, Terminated 1, Unknown 1 |
Follow edoxaban: new trials by email Literature Review of edoxaban trials Research Report on edoxaban
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism edoxaban, Apixaban - Venous Thromboembolism, Active Cancer | Phase 4 | Not yet recruiting | Samsung Medical Center | 2300 | 2026-11-01 | 2026-10-01 |
| Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease Edoxaban, Apixaban - Atrial Fibrillation (AF), Coronary Arterial Disease (CAD) | Phase 4 | Recruiting | Samsung Medical Center | 3000 | 2026-07-20 | 2026-08-10 |
| Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia Dabigatran, Apixaban, edoxaban - Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia | Phase 4 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 300 | 2026-01-15 | 2026-09-24 |
| Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE) Anticoagulant Oral - Atrium; Fibrillation, Chronic Kidney Diseases | Phase 4 | Recruiting | Hospital Sirio-Libanes | 1500 | 2024-12-18 | 2025-02-21 |
| The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet - Deep Vein Thrombosis, Pulmonary Embolism | Phase 4 | Active not recruiting | Herlev and Gentofte Hospital | 5000 | 2023-04-01 | 2025-05-15 |
| The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet - Atrial Fibrillation, Atrial Flutter | Phase 4 | Active not recruiting | Herlev and Gentofte Hospital | 11000 | 2023-04-01 | 2025-05-18 |
| Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation Edoxaban - Non-Valvular Atrial Fibrillation | Phase 4 | Completed | China National Center for Cardiovascular Diseases | 150 | 2022-03-30 | 2026-03-23 |
| Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation Direct Oral Anticoagulants - Atrial Fibrillation | Phase 4 | Recruiting | University of Birmingham | 3000 | 2021-06-01 | 2025-05-16 |
| EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) Edoxaban, Non-anticoagulant medical therapy - Intracranial Hemorrhages, Atrial Fibrillation | Phase 4 | Completed | Population Health Research Institute | 948 | 2019-09-20 | 2026-09-01 |
| Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic Therapy Edoxaban - Thromboembolism, Cancer | Phase 4 | Completed | Gruppo Oncologico Italiano di Ricerca Clinica | 150 | 2019-06-27 | 2023-05-30 |
| Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress Non-vitamin K oral anticoagulant (NOAC) - Stroke, Atrial Fibrillation | Phase 4 | Recruiting | Population Health Research Institute | 2270 | 2019-06-14 | 2026-01-12 |
| Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study 12-month Edoxaban, 3-month Edoxaban - Venous Thrombosis, Neoplasms | Phase 4 | Completed | Takeshi Morimoto | 605 | 2019-05-27 | 2023-10-04 |
| Resolution of Thrombi in Left Atrial Appendage With Edoxaban Edoxaban - Atrial Fibrillation, Left Atrial Appendage Thrombosis | Phase 4 | Completed | Keimyung University Dongsan Medical Center | 36 | 2019-05-19 | 2024-08-19 |
| Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease Edoxaban Monotherapy, Edoxaban plus Single Antiplatelet Agent - Atrial Fibrillation, Coronary Artery Disease | Phase 4 | Completed | Gi-Byoung Nam | 1040 | 2019-05-14 | 2024-06-10 |
| NOAC Plasma Concentration and Blood Coagulation in Healthy Volunteers Edoxaban 60 MG - Blood Coagulation Disorder | Phase 4 | Completed | Turku University Hospital | 15 | 2018-11-26 | 2019-09-17 |
| Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure Rivaroxaban, dabigatran, apixaban, or edoxaban, Clopidogrel -75 mg/day, Low dose aspirin -80 to 125 mg/day- - Left Atrial Appendage Closure, Thrombosis | Phase 4 | Active not recruiting | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | 510 | 2018-09-01 | 2026-03-27 |
| Lixiana Acute Stroke Evaluation Registry Edoxaban 60 MG, Edoxaban 30 mg - Ischemic Stroke, Atrial Fibrillation | Phase 4 | Completed | University of Alberta | 70 | 2018-06-01 | 2024-04-05 |
| Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy CE-mark approved LAA closure devices, Acetylsalicylic acid, Clopidogrel - Atrial Fibrillation | Phase 4 | Completed | Charite University, Berlin, Germany | 912 | 2018-02-28 | 2025-12-12 |
| A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure Edoxaban, WATCHMAN LAA Closure, Aspirin and Clopidogrel - Non-Valvular Atrial Fibrillation, Left Atrial Appendage Closure | Phase 4 | Unknown | Scripps Health | 75 | 2017-03-23 | 2017-07-11 |
| DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation DOAC, Aspirin - Ventricular Tachycardia, Premature Ventricular Contraction | Phase 4 | Completed | Kansas City Heart Rhythm Institute | 246 | 2017-02-16 | 2022-08-22 |
Showing 20 of 23. Sign in to see all of them.
Atrial Fibrillation (11) · Stroke (5) · Venous Thrombosis (3) · Atrial Flutter (2) · Coronary Artery Disease (2) · Neoplasms (2) · Pulmonary Embolism (2) · Angina, Stable (1) · Blood Coagulation Disorders (1) · Cerebral Hemorrhage (1) · Dementia (1) · Diabetes Mellitus (1) · Embolic Stroke (1) · Hemorrhage (1) · Hemorrhagic Stroke (1)
Herlev and Gentofte Hospital (2) · Population Health Research Institute (2) · Samsung Medical Center (2) · Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec (1) · Charite University, Berlin, Germany (1) · China National Center for Cardiovascular Diseases (1) · Electrophysiology Research Foundation (1) · Gi-Byoung Nam (1) · Gruppo Oncologico Italiano di Ricerca Clinica (1) · Hospital Sirio-Libanes (1) · Kansas City Heart Rhythm Institute (1) · Keimyung University Dongsan Medical Center (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Scripps Health (1) · Takeshi Morimoto (1)
United States (6) · Canada (5) · South Korea (5) · Denmark (3) · Germany (3) · India (3) · Italy (3) · United Kingdom (3) · Argentina (2) · Brazil (2) · China (2) · Finland (2) · Nepal (2) · Spain (2) · Switzerland (2)
Gunnar H Gislason, MD, PhD (2) · Ashkan Shoamanesh, MD, FRCPC (1) · Brian Buck, MD (1) · Carmine Pinto, MD (1) · David Conen, MD, MPH (1) · David Shukla (1) · Dhanunjaya Lakkireddy, MD (1) · Dipak Kotecha (1) · Dominick J Angiolillo, MD, PhD (1) · Duk-woo Park, MD (1) · Emily G McDonald, MD MSC (1) · Eun Kyoung Kim (1) · Giuseppe Derosa, MD, PhD, FESC (1) · John Camm (1) · Joo-yong Hahn, MD, PhD (1)
PMID 20665856, PMID 20723861, PMID 24682348, PMID 25060026, PMID 25604089, PMID 25777666, PMID 26993976, PMID 27765196, PMID 27931603, PMID 28065447, PMID 28145040, PMID 28231907, PMID 28495432, PMID 29146668, PMID 29183961, PMID 29622159, PMID 33868150, PMID 34022170, PMID 36700520, PMID 37390799, PMID 37638968, PMID 38650055, PMID 39225258, PMID 39921772, PMID 40766276, PMID 40875095, PMID 40930594, PMID 40946883, PMID 41139402, PMID 41387009, PMID 41679707, PMID 41762182, PMID 41848064, PMID 41849741, PMID 42003300, PMID 42459774, PMID 42690164
2019 (1), 2023 (1), 2025 (1)